// App-Quantinova.ai

7534 : Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

Researchers

Presenter

  • Rajat Bannerji

Principal Investigators

  • Sam Yuen

  • Tycel Jovelle Phillips

  • Christopher Arthur

  • Iris Isufi

  • Paula Marlton

  • John Francis Seymour

  • Paolo Corradini

  • Annalia Molinari

  • Giuseppe Gritti

  • Robert Emmons

  • Jamie Hirata

  • Lisa Musick

  • Sourish Saha

  • Brandon Croft

  • Christopher Flowers

Medical Centers

  • Rutgers Cancer Institute of New Jersey, Piscataway, NJ

  • New Brunswick, NJ

  • Calvary Mater Newcastle Hospital, Waratan, Australia

  • University of Michigan Medical School, Ann Arbor, MI

  • Royal North Shore Hospital, St Leonards, Australia

  • Yale New Haven Hospital, New Haven, CT

  • Princess Alexandra Hospital and University of Queensland, Brisbane, Australia

  • Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia

  • University of Milan and Istituto Nazionale Tumori, Milan, Italy

  • AUSL Romagna, Ospedale degli Infirmi, Rimini, Italy

  • Papa Giovanni XXIII Hospital, Bergamo, Italy

  • James Graham Brown Cancer Ctr, Louisville, KY

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche, Welwyn Garden City, United Kingdom

  • 1.MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • Australia

  • Italy

  • United Kingdom

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Polatuzumab vedotin

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Venetoclax

  • Recombinant human albumin

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02611323

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved